The Axiolabs Sermorelin 5mg vial sits in the growth hormone shelf at Best Anabolic Steroids: a lyophilised powder of the opening twenty-nine amino acids of the GHRH chain, dissolved in bacteriostatic water and injected under the skin. It is the signal that tells the pituitary to release growth hormone, not the hormone itself.
The historical context is worth knowing. The same fragment reached the pharmacy shelf decades ago under the brand name Geref for diagnostic use in children, and that product was later withdrawn; the vial sold today is a research material, not a continuation of that medicine. In competitive sport the whole GHRH family is prohibited at all times.
Product Overview
Growth hormone is not released continuously. The hypothalamus sends a pulse of releasing hormone, the pituitary answers with a burst of growth hormone, and the liver then produces IGF-1 as the downstream signal that does much of the work. An analogue of that releasing hormone therefore works upstream: it prompts the body's own pituitary rather than supplying a finished hormone, and the natural feedback loops still apply.
The practical consequence is speed and frequency. The parent compound is measured at roughly six minutes in rat studies after intravenous dosing, and supplier texts extend that to ten or twenty minutes without a human measurement behind it. Either way the signal is gone within the hour, so the reference protocols inject daily, typically before sleep when the natural pulse is largest. Body composition changes accumulate across months of that routine rather than in a short block.
Dosage Protocol
The figures below are vendor and reference amounts for a research vial, not an approved prescription. Sale of this exact material has never been licensed, so the ladder is a supplier gradation.
| Reconstitution | Add 1-2 ml of bacteriostatic water to the 5 mg vial for about 2.5-5 mg per ml |
| Base amount | The lower end of the vendor gradation, injected once daily |
| Higher amount | 400-500 mcg daily in the supplier scale, which is a research reference rather than a clinical dose |
| Timing | Daily, usually just before sleep and on an empty stomach |
| Course length | Twelve to sixteen weeks, then a break of four to six weeks |
| Women | The sources confirm no schedule for women |
At 5 mg per ml a 400 mcg amount draws 8 units on a U-100 syringe, and the same calculation at 2.5 mg per ml doubles the volume for the same amount. Getting that concentration written on the vial is the single most useful habit with this peptide, because daily use over three months means dozens of small draws.
Suggested Protocols
The characteristic pairing in this category is a releasing hormone with a ghrelin-receptor agonist. That is not a duplication: the two act at different receptors in the pituitary, and supplier protocols combine them to widen the pulse rather than to repeat one signal twice.
Because the peptide is not androgen related, a steroid cycle running beside it keeps its own rules: a long base such as Testaplex E 250, an inhibitor from the shelf such as Exeplex or Arimiplex when bloodwork calls for it, and the recovery agents Tamoxiplex 20 and Clomiplex 50 for after the last shot of that cycle.
What to Expect
- Sleep and recovery change first. Better sleep quality is the report that arrives earliest, weeks before any visible change in physique.
- The hormone response is a brief pulse. Growth hormone rises after each injection and then falls away, which is why the schedule is daily rather than weekly.
- Composition changes take a season. Twelve to sixteen weeks is the unit here, and stopping early wastes the slow build-up.
- No human half-life is established. The six minute figure belongs to rat research on the parent compound, and supplier figures of ten to twenty minutes are estimates.
- Human sports dosing is not confirmed. Reviewed sources describe the use of this peptide in deficiency states, not in healthy athletes, so the protocols are supplier guidance.
- Fluid and joint complaints appear with dose. Puffiness, aching joints and site reactions are the recurring complaints in the growth hormone peptide class.
Side Effects and Management
Between Courses and Follow-Up
No SERM-based recovery applies to this peptide. It stimulates growth hormone release rather than interacting with testosterone production, so the axis is untouched. What replaces post-cycle therapy is a scheduled pause and, if bloodwork is used, two markers worth following.
The wider catalogue, including growth hormone products, anti-estrogens and ancillary items, is gathered under the Axiolabs catalogue.
